Skip to main content

Table 1 Clinical and demographic characteristics of all patients, and stratified by BM response

From: Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)

Characteristics All pts, n = 58 BM-NR, n = 29 BM-PR, n = 16 BM-CR, n = 13
PV/ET, no. 27/31 15/14 5/11 7/6
Median age, years (range) 52 (19–75) 53 (19–72) 55 (33–70) 52 (23–75)
JAK2 V617F-positive patients, no (%) 42 (72) 22 (76) 9 (56) 11 (84)
Other driver mutations, no (%) CALR 6, MPL 2, TN 8 CALR 1, TN 6 CALR 5, MPL 2 TN 2
JAK2 V617F allele burden, median (range) 34 (3–89) 32.4 (3–82) 41 (18–89) 30 (5–76)
Abnormal karyotype, no 3 2 1
Median white blood cell count, 109/L (range) 9 (4–19) 9 (4–19) 9 (3–19) 8 (4–12)
Median hemoglobin, g/dL (range) 13 (9–19) 14 (12–17) 13 (9–18) 13 (12–19)
Median platelet count, 109/L (range) 721 (128–1646) 629 (185–1646) 866 (128–1423) 420 (236–1020)*
Significant splenomegaly, n (% of known)a 9/55 (16) 5/28 (18) 3/15 (20) 1/12 (8)
Disease-related symptoms, n (%) 30 (52) 17 (59) 6 (38) 7 (54)
No. of previously treated (%) 36 (62) 16 (55) 11 (69) 9 (69)
  1. * p value < 0.05
  2. aSignificant splenomegaly defined as a palpable spleen > 5 cm below costal margin (BCM), Abnormal karyotype: BM-PR: DER (13;22)(Q10;Q10) (n = 1), + MAR (n = 1), BM-CR: +1, DER (1;22)(Q10;Q10) (n = 1)